Your browser doesn't support javascript.
The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials.
Kow, Chia Siang; Lee, Learn-Han; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad; Ming, Long Chiau; Goh, Hui Poh.
  • Kow CS; School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
  • Lee LH; School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
  • Ramachandram DS; Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
  • Hasan SS; School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
  • Ming LC; Department of Pharmacy, University of Huddersfield, Huddersfield, UK.
  • Goh HP; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.
Immun Inflamm Dis ; 10(2): 255-264, 2022 02.
Article in English | MEDLINE | ID: covidwho-1589100
ABSTRACT

BACKGROUND:

Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease-2019 (COVID-19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID-19.

AIMS:

We aimed to perform a meta-analysis of randomized trials investigating the effect of colchicine in patients with COVID-19. MATERIALS &

METHODS:

We systematically searched electronic databases and clinical trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were all-cause mortality and duration of hospital stay. Meta-analysis with the random-effects model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% CI between colchicine users and non-colchicine users was estimated using Cohen's d index.

RESULTS:

The meta-analyses revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI 0.53-1.07), but a significant reduction in the duration of hospital stay with the use of colchicine (pooled standardized mean difference = -0.59; 95% CI -1.06 to -0.13). DISCUSSION AND

CONCLUSION:

The ability of colchicine to reduce the length of stay in hospitalized patients with COVID-19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of colchicine did not translate into mortality benefits in patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.562

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.562